Introduction
============

Type 2 diabetes mellitus is a major health problem associated with excess morbidity and mortality, resulting in substantial health-care costs \[[@B1]\]. Treatment of type 2 diabetes has traditionally focused on control of fasting plasma glucose; in recent years, the management of postprandial hyperglycemia has been thought to be a more important target. Glycated hemoglobin (HbA~1c~) levels are closely associated with postprandial glucose levels in type 2 diabetes, in comparison with fasting glucose levels \[[@B2]\]. Anti-hyperglycemic therapy focused on control of postprandial glucose level has a greater impact on overall metabolic control, and thus improves long-term outcome compared with the more traditional approaches focused on fasting glucose level \[[@B3]\]. Postprandial hyperglycemia has been associated with increased risk of microvascular \[[@B4]--[@B6]\] and macrovascular \[[@B7]--[@B10]\] complications. In recent years, cohort studies have shown that postprandial hyperglycemia is an independent risk factor for cardiovascular disease \[[@B11]--[@B13]\]. In the STOP-NIDDM study, correction of postprandial hyperglycemia reduced the onset of myocardial infarction \[[@B14]\].

The glycemic index (GI), originally described by Jenkins *et al.* \[[@B15]\], is a ranking of carbohydrates based on their immediate effects on blood glucose levels. Epidemiologic studies demonstrated that the dietary GI would be an important factor in preventing non-insulin-dependent diabetes \[[@B16], [@B17]\]. The beneficial effects of a low-GI diet have been demonstrated over both the short- and long-term for normal subjects and patients with diabetes \[[@B18]--[@B21]\]. It is difficult for individuals to strictly control every meal. Therefore, if a special meal is only given once a day, it could be useful to lower the postprandial serum glucose level and improve compliance. The quality of breakfast is thought to be the most important for improvement of glycemic control, because patients with diabetes require more insulin for breakfast than for an isocaloric midday or evening meal \[[@B22], [@B23]\]. Moreover, it has been reported that insulin sensitivity in individuals with diabetes fluctuated, with decreases from the night to morning and increases during the day \[[@B24]\].

A palatinose-based liquid formula (palatinose-formula, Inslow®: Meiji Dairy Products; Tokyo, Japan) is a recently developed liquid dietary product that contains palatinose. Palatinose a sucrose isomer found in honey \[[@B25]\], are metabolized by isomaltase, and less rapidly, but completely, cleaved in the intestine than sucrose \[[@B26]\]. Ingestion of palatinose by type 2 diabetic humans and rats resulted in a reduction in their postprandial plasma glucose and insulin levels \[[@B27], [@B28]\]. Consumption of palatinose-formula at breakfast appears to improve glycemic control by reducing postprandial plasma glucose and insulin levels after lunch (second meal effect) in healthy men \[[@B29]\]. However, it is not clear that the effect of continuous palatinose-formula intake at breakfast improves glucose metabolism in patients with impaired glucose tolerance (IGT) or type 2 diabetes. In this study we investigated the effects of long-term palatinose-formula ingestion as a part of breakfast on glycemic control and body composition in patients with IGT or type 2 diabetes.

Experimental Procedures
=======================

Liquid formulas
---------------

Palatinose-formula was prepared by partially replacing dextrin in the dextrin-based liquid formula (dextrin-formula) with 55.7% palatinose. The detailed composition is shown in Table [1](#T1){ref-type="table"}; it included palatinose, dextrin, xylitol, dietary fiber, and mixed carbohydrates. The protein, fat, and carbohydrate % of energy were 20.0%, 29.7%, and 50.3%, respectively. The control formula was a dextrin-formula that also contained sucrose; the protein, fat, and carbohydrate % of energy were 14.0%, 31.0%, and 55.0%, respectively (Table [1](#T1){ref-type="table"}).

Subjects and study design
-------------------------

The study was performed after obtaining written informed consent from all patients, and was approved by the Ethics Committee of the University of Tokushima. The protocol conformed to the Helsinki Declaration. Two patients with impaired glucose tolerance (IGT) (2 females) and 7 patients with type 2 diabetes (3 males and 4 females) participated in this study. Their clinical characteristics at study entry are shown in Table [2](#T2){ref-type="table"}. Patients with abnormal renal, hepatic, or thyroid function were excluded. Five patients were medicated with sulfonylurea or phenylalanine derivative and 4 patients were only received nutritional consultation. All patients maintained any current therapies throughout the study period, with no dosing changes. Prior to the beginning of the long-term palatinose-formula administration study, each patient underwent a palatinose-formula and dextrin-formula loading test.

Loading test
------------

The loading test had a crossover design, with a one-week washout period between dosing episodes. Each patient consumed both palatinose-formula (250 ml; 1046 kJ) and dextrin-formula (250 ml; 1046 kJ). The patients came to the University of Tokushima at 0830 h after a 12-h overnight fast. Patients completely consumed the liquid formula within a 5-min period. Peripheral venous blood samples were collected at times 0 (before ingestion), and 30, 60, 90, 120, and 180 min after ingestion of the formula. Blood samples were used for analysis of plasma glucose and insulin concentration.

Long-term study
---------------

The long-term study was carried out after a 3-month control period (from Month -3 to Month 0). The first month of the control period (from Month -3 to Month -2) was established to determine individual patient energy intake. Each patient's energy intake and dietary habits were determined from daily dietary records. Patients received individual counseling on dietary food intake and were recommended to reach a goal of a stable and reasonable energy intake. A 2-month control period (from Month -2 to Month 0) was arranged after the patients' quantity of energy intake was stabilized. After the control period, patients ingested palatinose-formula for 5 months (test period). During the test period, patients were instructed to maintain the quantity of total energy intake and substituted a palatinose-formula dose for 1046 kJ of their breakfast. The total energy of the breakfast in the test period was fixed to the control period (from Month -2 to Month 0) quantity based on each patient's dietary record. Patients were asked to maintain a constant lifestyle and keep a dietary record to be completed during the 3 days prior to each scheduled visit to the University of Tokushima. Visits were scheduled at Month -3, Month -2 (control period), and at Month 0 (baseline), 3, and 5 for collection of fasting blood samples, body composition measurement, and to hand in their previous 3-day's dietary records. Blood samples were used for analysis of fasting plasma glucose, fasting insulin, HbA~1c~, total cholesterol, HDL cholesterol, triacylglycerol, adiponectin and 8-hydroxydeoxyguanosine (8-OHdG) concentrations. A dietician calculated the quantity of intake energy from each patient's dietary records and determined the mean value for the 3 days leading up to the scheduled clinic visit.

Analytic methods
----------------

Body composition with respect to lean and fat mass was determined using a bioelectrical impedance analysis method (In Body 3.0; MP JAPAN, Tokyo, Japan).

Plasma samples were kept at −20°C until analyzed. Plasma glucose concentration was measured by using a glucose oxidase-based autoanalyzer. Serum insulin concentration was measured by a standard radioimmunoassay. The total incremental area under the curve (AUC) for plasma glucose and insulin were calculated for a 180-min period after ingestion of each liquid formula. The insulin resistance index was calculated using the homeostasis model assessment for insulin resistance (HOMA-IR = fasting insulin (µU/ml) × fasting glucose (mmol/L) / 22.5).

HbA~1c~ concentration was determined by high-performance liquid chromatography; serum triglyceride, total cholesterol, and HDL cholesterol concentrations were determined by enzymatic techniques using a Hitachi Model 736 autoanalyzer (Mito, Japan). Serum adiponectin concentrations were measured by human adiponectin ELISA kit (Otsuka Pharmaceutical Co, Ltd, Tokyo, Japan). Serum 8-OHdG concentrations were measured by high sensitive 8-OHdG ELISA kit (Japan Institute for the Control of Aging, Nikken SEIL Co., Ltd. Fukuroi; Shizuoka, Japan).

Statistical analyses
--------------------

Data are presented as mean ± standard error of the mean (SE). The loading test was analyzed using Student's *t* test for paired comparisons. The long-term study was analyzed using Wilcoxon matched-pairs signed-rank test. All statistical analyses were performed with Stat View for Windows, version 5.0 (SAS Institute; Cary, NC).

Results
=======

Loading test
------------

The effects of palatinose-formula administration on postprandial glucose and insulin levels were confirmed in patients with IGT and type 2 diabetes. Postprandial plasma glucose concentrations after palatinose-formula loading were significantly lower than those after dextrin-formula loading at 30 min (*p*\<0.01), 60 min (*p*\<0.01), and 90 min (*p*\<0.01) post-dosing (Fig. [1](#F1){ref-type="fig"}A). Postprandial insulin after palatinose-formula loading were lower than those after dextrin-formula loading at 30 min, 60 min, and 90 min post-dosing, but were not significantly different (Fig. [1](#F1){ref-type="fig"}B). Plasma glucose and insulin incremental AUCs after palatinose-formula loading were significantly lower than those after dextrin-formula loading (*p*\<0.05; Fig. [1](#F1){ref-type="fig"}C, D).

Long-term study
---------------

During the long-term study, two subjects withdrew due to conflicts of schedule and health problems unrelated to the study, and one subject was excluded from analysis due to poor compliance. Therefore, all long-term study data were analyzed and are presented for the six subjects (IGT; 2 females, type 2 diabetes; 1 male and 3 females) who completed the study. Serious side effects such as anemia, renal, or hepatic disorders did not appear during this study.

Daily intake of total energy at Month -2 decreased from that determined at the Month -3 visit, but there was no change in the daily total energy intake over subsequent control and test period. Macronutrients and dietary fiber intake from the control period to the test period did not change (Table [3](#T3){ref-type="table"}).

Anthropometric and laboratory parameters from the beginning of control period (Month -3) to the end of the test period (Month 5) are shown in Table [4](#T4){ref-type="table"}. Body weight, body mass index, and serum triacylglycerol concentration significantly decreased during the control period (possibly due to the nutritional consultation and subsequent dietary changes). No significant changes were observed in any other parameter during the control period. In the experimental period, no significant changes were observed in body weight, body mass index, body fat ratio, fasting plasma glucose, fasting insulin, triacylglycerol, total cholesterol, or HDL cholesterol levels. However, with intake of 1046 kJ palatinose-formula as a part of breakfast, HbA~1c~ and 8-OHdG levels were significantly decreased at the Month 3 and Month 5 evaluations. HOMA-IR slightly decreased and adiponectin slightly increased by palatinose-formula ingestion, although these changes were not statistically significant.

Discussion
==========

In this study, postprandial glucose and insulin levels after the ingestion of palatinose-formula diet were significantly lower than those after the ingestion of dextrin-formula diet in patients with IGT or type 2 diabetes, as previously observed in rats and healthy human subjects \[[@B29], [@B30]\]. Since energy amounts during the control and experimental periods were unchanged, it is conceivable that the decrease in HbA~1c~ and 8-OHdG concentrations is due to the effect of the long-term (5-month) ingestion of palatinose-formula as a part of breakfast in these patients with IGT or type 2 diabetes.

There are evidences of the beneficial effects to glycemic control of a low-GI diet in type 2 diabetes \[[@B18], [@B19], [@B21], [@B31]\], but there are few reports of the glycemic effects of a low-GI breakfast alone. Golay *et al.* found that switching from a standard cereal (cornflakes) to slow-release starch cereal (muesli) at breakfast for only 2 weeks improved carbohydrate metabolism and reduced insulin requirements in the insulin-treated type 2 diabetic patients \[[@B32]\]. In addition, it has been suggested that the low-glycemic-index foods consumed during the first meal improved glucose tolerance after the second meal, so-called "second meal effect" \[[@B33], [@B34]\]. In this study, long-term ingestion of palatinose-fomula diet as a part of breakfast decreased HbA1c concentration. In addition, decreased in HOMA-IR and increased in serum adiponectin level suggested that insulin sensitivity may also be ameliorated by long-term ingestion of palatinose formula. We previously reported that long-term ingestion of palatinose-formula over the long-term reduced visceral fat accumulation, improved insulin sensitivity in comparison with dextrin-formula \[[@B30]\], and increased adipocyte adiponectine gene expression in rats \[[@B35]\]. Adiponectine plays a role in glucose metabolism and plasma adiponectin level is positively correlated with insulin sensitivity \[[@B36]--[@B38]\]. These data suggest that long-term ingestion of palatinose-formula diet can improve glucose tolerance, probably due to the second meal effect.

In contrast, fasting plasma glucose levels did not change in this study. Avignon *et al.* suggested that postprandial hyperglycemia reflects better glycemic control than does fasting plasma glucose in patients with type 2 diabetes \[[@B2]\]. Additionally, lowering postprandial plasma glucose optimized overall glycemic control, thus improving long-term outcomes when compared with simply lowering fasting plasma glucose \[[@B3]\].

Serum 8-OHdG concentration after five months of treatment was also significantly reduced by palatinose-formula ingestion. Patients with type 1 and 2 diabetes have significantly higher 8-OHdG concentrations than do control subjects \[[@B39], [@B40]\]. Since 8-OHdG concentration was correlated with HbA~1c~ concentration \[[@B40], [@B41]\], reduced 8-OHdG reflected improvement of glycemic control by palatinose-formula ingestion. It is known that 8-OHdG can serve as a sensitive biomarker of oxidative DNA damage \[[@B42]\]. In a previous study, glucose fluctuations during postprandial periods exhibited a more specific triggering effect on oxidative stress than chronic sustained hyperglycemia in type 2 diabetes \[[@B43]\]. Oxidative stress triggers micro- and macrovascular complications \[[@B44]\]. Because ingesting palatinose-formula suppressed the postprandial glucose fluctuations, it might also reduce production of oxidative stress.

Because this study was carried out with a limited number of subjects, further study with larger populations should be initiated to support our findings. In conclusion, we suggest that long-term ingestion of palatinose-formula as a part of breakfast is effective in improving glycemic control for patients with IGT or type 2 diabetes.
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###### 

Energy composition of the test formulas

                                  Palatinose-formula   Dextrin-formula
  ------------------------------- -------------------- -----------------
  Energy (kJ/ml)                  4.18                 4.18
  Protein (% of energy)           20.0                 14.0
  Fat (% of energy)               29.7                 31.0
  Carbohydrate (% of energy)      50.3                 55.0
  Main carbohydrate composition   Palatinose (55.7%)   Dextrin (97.2%)

###### 

Subject Characteristics

  Characteristics                            Values
  ------------------------------------------ -------------
  Impaired glucose tolerance (male/female)   0/2
  Type 2 diabetes mellitus (male/female)     3/4
  Age (years)                                63.4 ± 3.0
  Body weight (kg)                           63.8 ± 2.5
  Body mass index (kg/m^2^)                  25.0 ± 0.8
  Body fat ratio (%)                         28.2 ± 2.2
  Fasting plasma glucose (mmol/L)            7.76 ± 0.45
  Fasting insulin (pmol/L)                   32.4 ± 3.0
  HbA~1c~ (%)                                6.60 ± 0.24
  Triacylglycerol (mmol/L)                   2.37 ± 0.40
  Total cholesterol (mmol/L)                 5.46 ± 0.29
  HDL cholesterol (mmol/L)                   1.36 ± 0.13

Values are means ± SE, *n* = 9.

###### 

Record of dietary intake during control and test periods

                          Control period   Test period                                  
  ----------------------- ---------------- -------------- -------------- -------------- --------------
  Energy (kJ/ml)          8335 ± 786       7690 ± 636     7577 ± 569     7627 ± 473     7707 ± 607
  Protein (g/day)         76.7 ± 8.6       77.8 ± 4.9     74.5 ± 7.2     78.2 ± 3.4     71.6 ± 3.3
   (% of energy)          15.4 ± 1.3       17.1 ± 0.8     16.4 ± 0.5     17.3 ± 0.6     15.8 ± 1.0
  Fat (g/day)             54.1 ± 4.6       52.3 ± 5.2     47.7 ± 4.2     48.5 ± 3.5     43.1 ± 2.6
   (% of energy)          24.3 ± 0.9       25.4 ± 1.5     23.3 ± 0.9     24.1 ± 2.0     21.3 ± 1.3
  Carbohydrate (g/day)    291.0 ± 34.4     260.4 ± 24.4   269.5 ± 21.3   262.6 ± 24.1   287.3 ± 32.6
   (% of energy)          60.3 ± 1.3       57.5 ± 1.4     60.2 ± 1.0     58.5 ± 2.3     62.9 ± 2.1
  Dietary fiber (g/day)   18.9 ± 1.0       20.6 ± 1.5     21.5 ± 1.7     21.0 ± 2.3     17.5 ± 1.7

Values are means ± SE, *n* = 6.

###### 

Anthropometric and laboratory parameters during control and test periods

                                     Control period   Test period                                  
  ---------------------------------- ---------------- -------------- ------------- --------------- ---------------
  Body weight (kg)                   64.9 ± 3.4\*     64.0 ± 3.2\*   63.3 ± 3.4    62.2 ± 3.4      62.4 ± 3.6
  Body mass index (kg/m^2^)          26.8 ± 1.5\*     26.4 ± 1.5     26.1 ± 1.6    25.7 ± 1.6      25.8 ± 1.7
  Body fat ratio (%)                 33.1 ± 2.4       32.4 ± 2.4     32.0 ± 2.6    31.1 ± 2.7      31.7 ± 2.9
  Fasting plasma glucose (mmol/L)    6.88 ± 0.45      6.96 ± 0.42    6.50 ± 0.26   6.73 ± 0.29     6.56 ± 0.26
  Fasting insulin (pmol/L)           39.2 ± 5.1       39.4 ± 10.3    41.8 ± 7.5    32.6 ± 5.6      35.0 ± 5.4
  HbA~1c~ (%)                        6.35 ± 0.18      6.20 ± 0.19    6.22 ± 0.19   5.90 ± 0.17\*   5.80 ± 0.15\*
  HOMA-IR                            1.98 ± 0.26      2.02 ± 0.51    2.00 ± 0.35   1.53 ± 0.27     1.67 ± 0.23
  Triacylglycerol (mmol/L)           2.15 ± 0.45\*    1.82 ± 0.32    1.51 ± 0.33   1.54 ± 0.33     1.53 ± 0.28
  Total cholesterol (mmol/L)         5.35 ± 0.27      5.18 ± 0.22    5.09 ± 0.09   5.03 ± 0.13     5.19 ± 0.28
  HDL cholesterol (mmol/L)           1.26 ± 0.12      1.32 ± 0.14    1.36 ± 0.17   1.28 ± 0.12     1.33 ± 0.17
  Adiponectin (mg/mL)                ---              ---            4.81 ± 0.50   ---             5.29 ± 0.66
  8-hydroxydeoxyguanosine (nmol/L)   ---              ---            1.36 ± 0.06   ---             0.93 ± 0.07\*

Values are means ± SE, *n* = 6. \* Different from Month 0 (baseline), *p*\<0.05.
